SCHEMBL21639769

SCHEMBL21639769

Brc1cccc(CSc2ncnc3[nH]cnc23)c1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 12/20 0.66
DBF4 Q9UBU7 12/20 0.66
HPGD P15428 3/20 0.47
ALOX15 P16050 1/20 0.47
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
LMNA P02545 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SLC29A1 Q99808 1/20 0.45
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31186618 1.00 CDC7 (0.66) CDC7DBF4HPGDALOX15MEN1
SCHEMBL21639771 0.85 CDC7 (0.66) CDC7DBF4HPGDALOX15L3MBTL1
SCHEMBL31186616 0.85 CDC7 (0.66) CDC7DBF4HPGDALOX15SLC29A1
SCHEMBL21639756 0.85 CDC7 (0.66) CDC7DBF4HPGDALOX15SLC29A1
SCHEMBL21639726 0.84 CDC7 (0.63) CDC7DBF4HPGDL3MBTL1LMNA
SCHEMBL31186608 0.84 CDC7 (0.63) CDC7DBF4HPGDL3MBTL1LMNA
SCHEMBL2120063 0.84 CDC7 (0.61) CDC7DBF4HPGDALOX15L3MBTL1
SCHEMBL31186612 0.84 CDC7 (0.61) CDC7DBF4HPGDALOX15L3MBTL1
SCHEMBL21639720 0.81 CDC7 (0.68) CDC7DBF4HPGDALOX15SLC29A1
SCHEMBL21639786 0.81 CDC7 (0.68) CDC7DBF4HPGDALOX15MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3604310-B1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CONSEJO SUPERIOR INVESTIGACION (ES) 2024-09-11 EP claimed
US-11446304-B2 CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2022-09-20 US claimed
US-20200093828-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2020-03-26 US claimed
EP-3604310-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-02-05 EP claimed
EP-3604310-B1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CONSEJO SUPERIOR INVESTIGACION (ES) 2024-09-11 EP disclosed
US-11446304-B2 CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2022-09-20 US disclosed
US-20200093828-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2020-03-26 US disclosed
EP-3604310-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Consejo Superior de Investigaciones Cientificas (CSIC) (ES) 2020-02-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200093828-A1 CDC-7-INHIBITOR COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS CDC7, TARDBP, CDC14A CDC7 1/4885DBF4 171/4885HPGD 4530/4885
US-11446304-B2 CDC-7-inhibitor compounds and use thereof for the treatment of neurological conditions CDC7, TARDBP, CDC14A CDC7 1/4885DBF4 171/4885HPGD 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.